News
NRBO
3.100
+1.30%
0.040
Weekly Report: what happened at NRBO last week (0415-0419)?
Weekly Report · 4d ago
Health Care Sector Update for 04/17/2024: VNDA, CLDX, NRBO
NASDAQ · 04/17 17:46
BUZZ-U.S. STOCKS ON THE MOVE-Outset Medical, Interactive Brokers, US energy sector
Wall Street's main indexes fell in choppy trading on Wednesday. The Dow Jones Industrial Average was down 0.05% and the S&P 500 and the Nasdaq Composite were both down. United Airlines Holdings was among the top percentage gainers. Downbeat earnings reports from some industry majors added to the losses.
Reuters · 04/17 17:33
BUZZ-NeuroBo Pharma rises as dosing begins in early-stage obesity trial
NeuroBo Pharmaceuticals rises as dosing begins in early-stage obesity trial. Shares of drug developer rise 8.2% to $3.68. Co says it has dosed its first patient in the first part of its two-part study. The drug, DA-1726, acts on a gut hormone to treat obesity.
Reuters · 04/17 15:15
NEUROBO PHARMACEUTICALS INC - FIRST PATIENT DOSED IN MULTIPLE ASCENDING DOSE PART 2 EXPECTED IN Q3 OF 2024
Reuters · 04/17 12:05
Weekly Report: what happened at NRBO last week (0408-0412)?
Weekly Report · 04/15 10:28
NeuroBo Pharmaceuticals Files For Mixed Shelf Offering Of Up To $150M
Benzinga · 04/12 20:13
NEUROBO PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $150 MLN- SEC FILING
Reuters · 04/12 20:08
Weekly Report: what happened at NRBO last week (0401-0405)?
Weekly Report · 04/08 10:31
NEUROBO PHARMACEUTICALS INC: FULL DATA READOUT EXPECTED IN SECOND HALF OF 2024
Reuters · 04/01 12:01
Weekly Report: what happened at NRBO last week (0325-0329)?
Weekly Report · 04/01 10:31
Neurobo Pharmaceuticals Inc: Annual report
Press release · 03/28 22:20
NeuroBo Pharmaceuticals GAAP EPS of -$2.46
NeuroBo Pharmaceuticals, Inc. Reports FY GAAP EPS of -$2.46. Cash was $22.4 million as of December 31, 2023, compared with $33.4m as of 2022. The company expects to report its first quarterly results in 2024.
Seeking Alpha · 03/28 19:02
Press Release: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals reports Year End 2023 Financial Results and Provides Corporate Update. Received first site approval to proceed with the Phase 1 Trial of DA-1726 in Obesity. Received Safety Review Committee approval for DA-1241 for the Treatment of MASH. First Patient expected to be dosed in the second quarter of 2024. Company has cash of $22.4 million.
Dow Jones · 03/28 12:01
Weekly Report: what happened at NRBO last week (0318-0322)?
Weekly Report · 03/25 10:33
Weekly Report: what happened at NRBO last week (0311-0315)?
Weekly Report · 03/18 10:31
BUZZ-U.S. STOCKS ON THE MOVE-Vera Bradley, Rumble, Nvidia
The tech-laden Nasdaq fell on Wednesday as rising U.S. Treasury yields hit market-moving growth stocks. The Dow Jones Industrial Average was up 0.30% at 39,123.73. Williams-Sonoma was the top percentage gainer on the S&P 500.
Reuters · 03/13 18:16
BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, US energy sector, gold miners
Dow Jones Industrial Average up 0.41% but Nasdaq down 0.70%. Top three S&P 500 percentage gainers: Williams-Sonoma, Freeport-McMoRan. U.S. Treasury yields rise as investors await more data on the timing of interest-rate cuts.
Reuters · 03/13 16:05
NeuroBo Phase 2a study for MASH drug to proceed as planned
Healthcare NeuroBo Phase 2a study for MASH drug to proceed as planned. The company is testing DA-1241 for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH. NeuroBo Pharmaceuticals said a safety review committee has recommended the study continue.
Seeking Alpha · 03/13 15:06
BUZZ-U.S. STOCKS ON THE MOVE-Nucor, ADM, SilverBow Resources
U.S. Stock index futures were muted on Wednesday. Dow e-minis were up 0.10% at 39,072. The top two NYSE percentage gainers premarket were Li-Cycle Holdings and Barnes & Noble. Investors await a slew of economic data for clues on the timing of the Fed's interest-rate cuts.
Reuters · 03/13 13:19
More
Webull provides a variety of real-time NRBO stock news. You can receive the latest news about Neurobo Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.